B. Ness

发表

Construction and Functional Analysis of Human Genetic Interaction Networks with Genome-wide Association Data

M. Steinbach, Vipin Kumar, C. Myers, 2011, 1101.3343.

Distinct IL-6 signal transduction leads to growth arrest and death in B cells or growth promotion and cell survival in myeloma cells

B. Ness, W. Cheung, 2002, Leukemia.

The polycomb group protein enhancer of zeste homolog 2 (EZH2) is an oncogene that influences myeloma cell growth and the mutant ras phenotype

B. Ness, P. Croonquist, Paula A. Croonquist, 2005, Oncogene.

Managing incidental findings and research results in genomic research involving biobanks and archived data sets

Robert C. Green, Judy Illes, Isaac S. Kohane, 2012, Genetics in Medicine.

Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group

Kenneth C. Anderson, Benjamin Djulbegovic, Bart Barlogie, 2003, British journal of haematology.

Deletions of chromosome 13 in multiple myeloma identified by interphase FISH usually denote large deletions of the q arm or monosomy

R. Fonseca, B. Ness, D. Harrington, 2001, Leukemia.

Return of individual research results and incidental findings in the clinical trials cooperative group setting

B. Ness, M. Ferriere, 2012, Genetics in Medicine.

Mapping the inputs, analyses, and outputs of biobank research systems to identify sources of incidental findings and individual research results for potential return to participants

B. Ness, S. Wolf, Heather R. Bemmels, 2012, Genetics in Medicine.

The development of novel targeted therapeutics for treatment of multiple myeloma research roundtable

E. Sausville, B. Barlogie, K. Anderson, 2003 .

Profiling Bortezomib Resistance in Multiple Myeloma: Implications in Personalized Pharmacotherapy

J. Shaughnessy, B. Ness, A. Mitra, 2014 .

Molecular genetics of human multiple myeloma

B. Ness, 1990 .

Interferon-α protects myeloma cell lines from dexamethasone-induced apoptosis

B. Ness, M. Oken, P. Liu, 1999, Leukemia.

Plasma Cells, and Their Progenitors Survival Requirements for Memory B Cells, Deregulation of c-Myc Confers Distinct

B. Ness, S. Janz, L. Erickson, 2008 .

Clinical significance of TP53 mutation in myeloma

R. Fonseca, B. Ness, M. Oken, 2007, Leukemia.

human kappa light-chain enhancer. Identification of an octamer-binding site in the

B. Ness, K. Nelms, 2013 .

Identification ofan Octamer-Binding SiteintheHumanKappa Light-Chain Enhancer

B. Ness, K. Nelms, 1990 .

Induced Rearrangement of K Genes in the BLIN-1 Human Pre-B Cell Line Correlates with Germline

B. Ness, T. Lebien, D. Martin, 1991 .

Reduced CXCR4 expression is associated with extramedullary disease in a mouse model of myeloma and predicts poor survival in multiple myeloma patients treated with bortezomib

F. Zhan, B. Ness, S. Janz, 2013, Leukemia.

of multiple myeloma patients Detection and quantitation of malignant cells in the peripheral blood

B. Ness, M. Oken, R. Kyle, 2011 .

Lymphoid lineage‐associated features in acute myeloid leukaemia: phenotypic and genotypic correlations

B. Ness, J. Bennett, E. Paietta, 1992, British journal of haematology.

Single-Cell Transcriptomics Identifies Intra-Tumor Heterogeneity in Human Myeloma Cell Lines

B. Ness, A. Mitra, M. Linden, 2014 .

Initiation andProcessing ofTwoKappaImmunoglobulin GermLine Transcripts inMouseB Cells

B. Ness, D. Martin, 1990 .

Clinical and biological significance of RAS mutations in multiple myeloma

R. Fonseca, B. Ness, M. Oken, 2008, Leukemia.

International Myeloma Working Group molecular classification of multiple myeloma: spotlight review

B. Barlogie, J. Shaughnessy, G. Morgan, 2009, Leukemia.

Original Article Interaction of CYP1B1, cigarette-smoke carcinogen metabolism, and lung cancer risk

M. Haznadar, B. Ness, M. Oken, 2010 .

Interaction of CYP 1 B 1 , cigarette-smoke carcinogen metabolism , and lung cancer risk

M. Haznadar, B. Ness, M. Oken, 2010 .

Activation of N-ras and K-ras induced by interleukin-6 in a myeloma cell line: implications for disease progression and therapeutic response

B. Ness, M. Rowley, Matthew A Rowley, 2002, Oncogene.

The bone marrow stromal microenvironment influences myeloma therapeutic response in vitro

B. Ness, W. Cheung, 2001, Leukemia.

Line ANBL 6 Characteristics of the Interleukin 6-dependent Myeloma Cell Oncogene Alters the Growth ras Introduction of an Activated N-Updated

B. Ness, T. Lebien, N. Shah, 2006 .

Transcription of the unrearranged mouse Cκ locus: Sequence of the initiation region and comparison of activity with a rearranged Vκ-Cκ gene

B. Ness, R. Perry, M. Weigert, 1981, Cell.

A Genome-Wide Association Study Identifies A New Ovarian Cancer Susceptibility Locus On 9 p 22 . 2

Aleksandra, Galina, David, 2010 .

Sequential analysis of bone marrow and peripheral blood after stem cell transplant for myeloma shows disparate tumor involvement

F. Prósper, B. Ness, C. Verfaillie, 1997, Leukemia.

Molecular Genetics of Myeloma

B. Ness, 2013 .

Corrective Recombination ofMouseImmunoglobulin KappaAlleles inAbelson MurineLeukemia Virus-Transformed Pre-BCells

B. Ness, R. Feddersen, 1990 .

New technologies in the myeloma gene mine.

B. Ness, 2002 .

Induced k Receptor Editing Shows No Allelic Preference in a Mouse Pre-B Cell Line

B. Ness, M. Linden, Xiangdong Liu, 2000 .

Tools and Technologies Pro fi ling Bortezomib Resistance Identi fi es Secondary Therapies in a Mouse Myeloma Model

C. Myers, F. Zhan, B. Ness, 2013 .

Genetic polymorphisms of EPHX1, Gsk3β, TNFSF8 and myeloma cell DKK-1 expression linked to bone disease in myeloma

O. Stephens, B. Barlogie, J. Shaughnessy, 2009, Leukemia.

Pharmacogenomics education, research and clinical implementation in the state of Minnesota.

C. Aliferis, R. S. Huang, B. Ness, 2021, Pharmacogenomics.

Genomic Research and Incidental Findings

B. Ness, Brian G Van Ness, 2008 .

Characterization of the Predominant T-Cell Receptor Delta (TCRδ) Rearrangements in Non-T, Non-B ALL

B. Ness, J. Kersey, F. Griesinger, 1992 .

Characterizing Discriminative Patterns pdf

Vipin Kumar, Michael S. Steinbach, Gang Fang, 2011, ArXiv.

Activating Mutations in the Nand Kras Oncogenes Differentially Affect the Growth Properties of the IL-6-dependent Myeloma Cell Line ANBL 6 '

B. Ness, Liu, D. Jelinek, 2006 .

Genetic Associations with Bortezomib Mediated Neuropathy in Multiple Myeloma.

H. Goldschmidt, G. Morgan, P. Sonneveld, 2009 .

multiple myeloma patients an Eastern Cooperative Oncology Group phase 3 trial for newly diagnosed Blood levels of immune cells predict survival in myeloma patients: results of

B. Ness, M. Oken, R. Kyle, 2013 .

Plasmablastic morphology--an independent prognostic factor with clinical and laboratory correlates: Eastern Cooperative Oncology Group (ECOG) myeloma trial E9486 report by the ECOG Myeloma Laboratory Group.

B. Klein, B. Ness, M. Oken, 1998, Blood.

Blood levels of immune cells predict survival in myeloma patients: results of an Eastern Cooperative Oncology Group phase 3 trial for newly diagnosed multiple myeloma patients.

B. Ness, M. Oken, R. Kyle, 2001, Blood.

High-throughput drug screening identifies compounds and molecular strategies for targeting proteasome inhibitor-resistant multiple myeloma

C. Myers, B. Ness, T. Xia, 2014, Leukemia.

ADP-ribosylation of elongation factor 2 by diphtheria toxin. NMR spectra and proposed structures of ribosyl-diphthamide and its hydrolysis products.

B. Ness, J. Howard, B. V. Van Ness, 1980, The Journal of biological chemistry.

Activating mutations of N- and K-ras in multiple myeloma show different clinical associations: analysis of the Eastern Cooperative Oncology Group Phase III Trial.

B. Ness, M. Oken, R. Kyle, 1996, Blood.

Unexpected immunoglobulin light chain gene rearrangements in myeloid antigen positive acute lymphoid leukemia.

B. Ness, J. Bennett, B. V. Van Ness, 1991, Leukemia research.

The bone marrow of multiple myeloma patients contains B cell populations at different stages of differentiation that are clonally related to the malignant plasma cell

B. Ness, B. V. Van Ness, D. Billadeau, 1993, The Journal of experimental medicine.

Erratum: Myeloma management guidelines: A consensus report from the scientific advisors of the international myeloma foundation (The Hematology Journal (2003) vol, 4 (379-398) 10.1038/sj.thj.6200312)

G. Morgan, P. Sonneveld, J. Miguel, 2004 .

lymphoproliferative disease and plasma cell malignancies Targeted overexpression of Bcl-XL in B-lymphoid cells results in

B. Ness, M. Linden, N. Kirchhof, 2013 .

The Genetic Contribution to the Aetiology of Thalidomide Associated VTE.

H. Goldschmidt, B. Barlogie, J. Shaughnessy, 2006 .

Site-specific cleavage of supercoiled DNA by ascorbate/Cu(II).

B. Ness, B. V. Van Ness, Y. Wang, 1989, Nucleic acids research.

Prognostic significance of the S‐phase fraction of light‐chain‐restricted cytoplasmic immunoglobulin (cIg) positive plasma cells in patients with newly diagnosed multiple myeloma enrolled on eastern cooperative oncology group treatment trial E9486

B. Ness, M. Oken, J. Katzmann, 1999, American journal of hematology.

Detection and quantitation of malignant cells in the peripheral blood of multiple myeloma patients.

B. Ness, M. Oken, R. Kyle, 1992, Blood.

Analysis of B-lymphoid malignancies using allele-specific polymerase chain reaction: a technique for sequential quantitation of residual disease.

B. Ness, M. Oken, R. Kyle, 1991, Blood.